Mucopolysaccharidosis Treatment Market Size

Mucopolysaccharidosis Treatment Market size was over USD 10.79 Billion in 2023 and is likely to exceed USD 28.99 Billion by the end of 2036, growing at over 7.9% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of mucopolysaccharidosis treatment is evaluated at USD 11.56 Billion. HSCT, also known as bone marrow transplant, involves replacing the patient's faulty bone marrow or stem cells with healthy donor cells that produce the missing enzyme. In addition to these established treatments, ongoing research and development efforts were focused on finding new therapies and improving existing ones. These efforts might include gene therapy, small molecule drugs, and other innovative approaches aimed at addressing the underlying genetic and biochemical factors contributing to MPS.

Mucopolysaccharidosis (MPS) refers to a group of rare genetic disorders known as lysosomal storage disorders. These disorders are characterized by the accumulation of glycosaminoglycans (GAGs) due to the deficiency of specific enzymes required for their breakdown within lysosomes. This leads to a range of symptoms and complications affecting various organs and systems in the body.